Biophysical characterisation, antitumor activity and MOF encapsulation of a half-sandwich ruthenium(ii) mitoxantronato system
- 1 November 2013
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 2 (17), 2473-2477
- https://doi.org/10.1039/c3tb21455a
Abstract
The novel non-conventional metallodrug [(η6-p-cymene)2Ru2mitoxantronato]Cl2 (1) exhibits redox activity, DNA intercalation ability, cathepsin B and D inhibition and in vitro antitumor activity able to circumvent cisplatin resistance. Moreover, 1 can be successfully incorporated into MIL100(Fe) as a proof of concept of the feasibility of metal–organic frameworks as carriers of non-conventional drugs.Keywords
This publication has 27 references indexed in Scilit:
- New Uses for Old Drugs: Attempts to Convert Quinolone Antibacterials into Potential Anticancer Agents Containing RutheniumInorganic Chemistry, 2013
- Next-Generation Anticancer MetallodrugsCurrent Topics in Medicinal Chemistry, 2012
- A Potent Ruthenium(II) Antitumor Complex Bearing a Lipophilic Levonorgestrel GroupInorganic Chemistry, 2011
- Molecular architecture of redox-active half-sandwich Ru(ii) cyclic assemblies. Interactions with biomolecules and anticancer activityCrystEngComm, 2010
- Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFTDalton Transactions, 2010
- Current applications and future potential for bioinorganic chemistry in the development of anticancer drugsDrug Discovery Today, 2009
- Areneruthenium complexes as anticancer agentsDalton Transactions, 2009
- Recent developments in ruthenium anticancer drugsMetallomics, 2009
- In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA ComplexesJournal of Medicinal Chemistry, 2005
- Intercalation of Pharmorubicin Anticancer Drug to DNA Studied by Cyclic Voltammetry with Analytical ApplicationsAnalytical Letters, 1999